196 related articles for article (PubMed ID: 16614977)
1. Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Dig Dis Sci; 2006 Mar; 51(3):618-22. PubMed ID: 16614977
[TBL] [Abstract][Full Text] [Related]
2. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
3. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
4. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
[TBL] [Abstract][Full Text] [Related]
5. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
8. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
10. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
[TBL] [Abstract][Full Text] [Related]
11. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
[TBL] [Abstract][Full Text] [Related]
12. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
13. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
[TBL] [Abstract][Full Text] [Related]
14. Primary sclerosing cholangitis.
Stiehl A; Benz C; Sauer P
Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
[TBL] [Abstract][Full Text] [Related]
15. Effect of colectomy with ileo-anal anastomosis on the biliary lipids.
Galatola G; Fracchia M; Jazrawi RP
Eur J Clin Invest; 1995 Jul; 25(7):534-8. PubMed ID: 7556373
[TBL] [Abstract][Full Text] [Related]
16. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
Gilger MA; Gann ME; Opekun AR; Gleason WA
J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Rust C; Beuers U
Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]